Optimizing Intrahepatic Cholangiocarcinoma Staging


Denizmen Zorba D., Arslan D. F., Sanli Y., Kuyumcu S.

CLINICAL NUCLEAR MEDICINE, cilt.51, sa.8, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 8
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1097/rlu.0000000000006310
  • Dergi Adı: CLINICAL NUCLEAR MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Herein, we present a case of a patient with intrahepatic cholangiocarcinoma (ICC) who underwent [18F]FDG, [68Ga]Ga-Trivehexin, and [68Ga]Ga-FAPI-04 PET/CT scans for initial staging. The primary liver lesion demonstrates progressively increased uptake across all 3 tracers, whereas metastatic cervical lymph nodes are visualized with [68Ga]Ga-FAPI-04 PET/CT and [68Ga]Ga-Trivehexin but not with [18F]FDG; importantly, [68Ga]Ga-FAPI-04 PET/CT, in addition, delineates metastatic abdominal lymph nodes. This case highlights that [68Ga]Ga-Trivehexin PET/CT may serve as an alternative to [18F]FDG PET/CT, warranting reevaluation of FDG limitations, while FAPI remains a strong competitor to both.